

DAFTAR PUSTAKA

- Afonso JP., Freitas R., António Morais FL., Oliveira J., Amaro T., Reis RM., Baltazar FM., Longatto-Filho A., Santos LL., 2015. *Urothelial bladder cancer progression: lessons learned from the bench*. Journal of Cancer Metastasis and Treatment;1:57-66.
- Azuma T., Yao S., Zhu G., Flies AS., Flies SJ, Chen L., 2008. *B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells*. Blood, The Journal of the American Society of Hematology;111(7):3635-43.
- Babjuk M., Burger M., Comperat E., Palou J., Rouprêt M., van Rhijn B., Shariat S., Sylvester R., Zigeuner R., Gontero P., Mostafid H. Reply to Harry Herr's Letter to the Editor Re: Marko Babjuk., Andreas Böhle., Maximilian Burger., Et Al., 2017. *EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016*. Euro Urology ; 71: 447-61.
- Bellmunt J., Mullane SA., Werner L., Fay AP., Callea M., Leow JJ., Taplin ME., Choueiri TK., Hodi FS., Freeman GJ., Signoretti S., 2015. *Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma*. Annals of oncology;26(4):812-7.
- Bellmunt J., Powles T., Vogelzang NJ., 2017. *A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now*. Cancer treatment reviews;54:58-67.
- Boorjian SA., Sheinin Y., Crispen PL., Farmer SA., Lohse CM., Kuntz SM., Leibovich BC., Kwon ED., Frank I., 2008. *T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival*. Clinical cancer research;14(15):4800-8.
- Brown JA., Dorfman DM., Ma FR., Sullivan EL., Munoz O., Wood CR., Greenfield EA., Freeman GJ., 2003. *Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production*. The Journal of Immunology;170(3):1257-66.
- Chen BJ., Chapuy B., Ouyang J., et al., 2013. *PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies*. Clin Cancer Res ;19: 3462–73.
- Colin P., Koenig P., Ouzzane A., Berthon N., Villers A., Biserte J., Rouprêt M., 2009. *Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract*. BJU international;104(10):1436-40.
- Compérat EM., Burger M., Gontero P., Mostafid AH., Palou J., Rouprêt M., van Rhijn BW., Shariat SF., Sylvester RJ., Zigeuner R., Babjuk M., 2019. *Grading of urothelial carcinoma and the new “World Health Organisation classification of Tumours of the urinary system and male genital organs 2016”*. European urology focus;5(3):457-66.

- Dalbagni G., Genega E., Hashibe MI., Zhang ZF., Russo P., Herr H., Reuter V., 2001. *Cystectomy for bladder cancer: a contemporary series*. The Journal of urology;165(4):1111-6.
- Del Alba AG., De Velasco G., Lainez N., Maroto P., Morales-Barrera R, Muñoz-Langa J., Pérez-Valderrama B., Basterretxea L., Caballero C., Vazquez S., 2019. *SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer*. Clinical and Translational Oncology;21(1):64-74.
- Deuker M., Martin T., Stolzenbach F., Rosiello G., Ruvolo CC., Nocera L., Tian Z., Becker A., Kluth L., Roos FC., Tilki D., 2021. *Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stadiums and treatment modalities*. Clinical genitourinary cancer;19(1):60-8.
- Ding X, Chen Q., Yang Z., Li J., Zhan H., Lu N., Chen M., Yang Y., Wang J., Yang D., 2019. *Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis*. Cancer management and research;11:4171.
- Eich ML., Chaux A., Guner G., Taheri D., Rodriguez MA., Peña MD., Baras AS., Hahn NM., Drake C., Sharma R., Bivalacqua TJ., 2019. *Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder*. Human pathology;89:24-32.
- Gao Q., Wang XY., Qiu SJ., Yamato I., Sho M., Nakajima Y., Zhou J., Li BZ., Shi YH., Xiao YS., Xu Y., 2009. *Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma*. Clinical Cancer Research;15(3):971-9.
- Ghiotto M., Gauthier L., Serriari N., Pastor S., Truneh A., Nunès JA., Olive D., 2010. *PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1*. International immunology;22(8):651-60.
- Grollman AP., Jelaković B., 2007. *Role of environmental toxins in endemic (Balkan) nephropathy*. Journal of the American Society of Nephrology;18(11):2817-23.
- Grossfeld GD., Carroll P., 2004. *Urothelial Carcinoma: cancers of the bladder, ureter and renal pelvis*. Smith's general urology;16:324-45.
- Holmang S., Johansson SL., 2004. *Synchronous bilateral ureteral and renal pelvic carcinomas: Incidence, etiology, treatment, and outcome*. Cancer;101(4):741-7.
- Horstmann M., Witthuhn R., Falk M., Stenzl A., 2008. *Gender-specific differences in bladder cancer: a retrospective analysis*. Gender medicine;5(4):385-94.
- Humphrey PA., Moch H., Cubilla AL., Ulbright TM., Reuter VE., 2016. *The 2016 WHO classification of tumours of the urinary system and male genital organs—part B: prostate and bladder tumours*. European urology. 2016;70(1):106-19.

- Inman BA., Sebo TJ., Frigola X., Dong H., Bergstralh EJ., Frank I., Fradet Y., Lacombe L., Kwon ED., 2007. *PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stadium progression*. Cancer: Interdisciplinary International Journal of the American Cancer Society;109(8):1499-505.
- Keir ME., Butte MJ., Freeman GJ., Sharpe AH., 2008. *PD-1 and its ligands in tolerance and immunity*. Annu. Rev. Immunology;26:677-704.
- Kim HS., Jang WS., Ham WS., Jung SI., Lee DH., Ku JH., Ha HK., Ku JY., Choi SY., Chang IH., Choi T., 2020. *Programmed cell death-ligand 1 expression status in urothelial carcinoma according to clinical and pathological factors: a multi-institutional retrospective study*. Frontiers in Oncology;10.
- Kim JM., Chen DS., 2016. *Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)*. Annals of Oncology;27(8):1492-504.
- Lopez-Beltran A., Montironi R., 2004. *Non-invasive urothelial neoplasms: according to the most recent WHO classification*. European urology;46(2):170-6.
- Margulis V., Shariat SF., Matin SF., Kamat AM., Zigeuner R., Kikuchi E., Lotan Y., Weizer A., Raman JD., Wood CG., Upper Tract Urothelial Carcinoma Collaboration., 2009. *Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration*. Cancer. 15;115(6):1224-33.
- Mishra V., Balasubramaniam G., 2020. *Urinary bladder cancer and its associated factors—An epidemiological overview*. Indian Journal of Medical Sciences;1-9.
- Miyazaki J., Nishiyama H., 2017. *Epidemiology of urothelial carcinoma*. International Journal of Urology;24(10):730-4.
- Murta-Nascimento C., Schmitz-Drager BJ., Zeegers MP., Steineck G., Kogevinas M., Real FX., et al., 2007. *Epidemiology of urinary bladder cancer: from tumor development to patient's death*. World J Urol; 25(3): 285- 295.
- Nakanishi J., Wada Y., Matsumoto K., Azuma M., Kikuchi K., Ueda S., 2007. *Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers*. Cancer Immunology, Immunotherapy;56(8):1173-82.
- Nechifor-Boila IA., Loghin A., Nechifor-Boila A., Decaussin-Petrucci M., Voidazan S., Chibelea BC., Martha O., Borda A., 2021. *PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy*. Life;11(5):404.

- Pedoeem A., Azoulay-Alfaguter I., Strazza M., Silverman GJ., Mor A. Programmed death-1 pathway in cancer and autoimmunity. *Clin Immunol* 2014;153:145–52. 7. Dong H., Zhu G., Tamada K., Chen L., 1999. *B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion*. *Nat Med*;5:1365–9.
- Rouprêt M., Babjuk M., Compérat E., Zigeuner R., Sylvester RJ., Burger M., Cowan NC., Gontero P., Van Rhijn BW., Mostafid AH., Palou J., 2018. *European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update*. *European urology*;73(1):111-22.
- Saginala K., Barsouk A., Aluru JS., Rawla P., Padala SA., Barsouk A., 2020. *Epidemiology of bladder cancer*. *Medical Sciences*;8(1):15.
- Shariat SF., Favaretto RL, Gupta A., Fritsche HM., Matsumoto K., Kassouf W., Walton TJ., Tritschler S., Baba S., Matsushita K., Bastian PJ., 2011. *Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma*. *World journal of urology*;29(4):481-6.
- Siegel RL, Miller KD., Jemal A., 2016. *Cancer statistics, 2016*. *CA: a cancer journal for clinicians*;66(1):7-30.
- Skala SL., Liu TY., Udager AM., Weizer AZ., Montgomery JS., Palapattu GS., Siddiqui J., Cao X., Fields K., Abugharib AE., Soliman M., 2017. *Programmed death-ligand 1 expression in upper tract urothelial carcinoma*. *European urology focus*;3(4-5):502-9.
- Song W., Shen L., Wang Y., Liu Q., Goodwin TJ., Li J., Dorosheva O., Liu T., Liu R., Huang L., 2018. *Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap*. *Nature communications*;9(1):1-1.
- Tanaka MF., Sonpavde G., 2011. *Diagnosis and management of urothelial carcinoma of the bladder*. *Postgraduate medicine*;123(3):43-55.
- Topalian SL., Hodi FS., Brahmer JR., Gettinger SN., Smith DC., McDermott DF., Powderly JD., Carvajal RD., Sosman JA., Atkins MB., Leming PD., 2012. *Safety, activity, and immune correlates of anti-PD-1 antibody in cancer*. *New England Journal of Medicine*;366(26):2443-54.
- Wang Y., Zhuang Q., Zhou S., Hu Z., Lan R., 2009. *Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance*. *J Huazhong Univ Sci Technolog Med Sci*; 29:77-9.
- Xylinas E., Robinson BD., Kluth LA., Volkmer BG., Hautmann R., Küfer R., Zerbib M., Kwon E., Thompson RH., Boorjian SA., Shariat SF., 2014. *Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder*. *European Journal of Surgical Oncology (EJSO)*;40(1):121-7.

- Yearley JH., Gibson C., Yu N., Moon C., Murphy E., Juco J., Lunceford J., Cheng J., Chow LQ., Seiwert TY., Handa M., 2017. *PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer*. Clinical cancer research;23(12):3158-67.
- Yu WB., Rao JY., 2019. *Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma*. Chronic diseases and translational medicine;5(3):170-7.
- Zhu L., Sun J., Wang L., Li Z., Wang L., Li Z., 2019. *Prognostic and clinicopathological significance of PD-L1 in patients with bladder cancer: a meta-analysis*. Frontiers in pharmacology;10:962.